ArticleScientific reports2017

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Vikas Dembla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.